<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522078</url>
  </required_header>
  <id_info>
    <org_study_id>15-0115</org_study_id>
    <nct_id>NCT02522078</nct_id>
  </id_info>
  <brief_title>Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion</brief_title>
  <acronym>MisoWet</acronym>
  <official_title>Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion - A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to verify whether the moisture of 400 µg of misoprostol pre uterine
      evacuation increases the dilatation of uterine cervix compared to dry misoprostol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Misoprostol is the most widely used drug for abortion due to its low cost, stability and easy
      to use regimen. Nevertheless, there is a debate whether the administration of dry misoprostol
      has similar effects compared to wet pill. It would be necessary to undertake a clinical trial
      to evaluate which regimen (dry or wet) offers a better cervical dilation pre uterine
      evacuation. The primary objective of this study is to compare the degree of cervical
      dilatation pre-uterine evacuation in subject that received 400 µg of dry or wet misoprostol 3
      or more hours before the procedure. Secondary objective is to verify whether there is a
      correlation between vaginal pH (&lt;5 / ≥5) and the degree of cervical dilation (≥8mm / &lt;8mm)
      with the use of wet or dry misoprostol. Women will be randomized to one of the two groups:
      dry or wet misoprostol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical dilation</measure>
    <time_frame>3 to 4 hours after putting misoprostol into the vagina</time_frame>
    <description>Cervical dilation will be measure with Karman cannulas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal acidity - hydrogen ion concentration</measure>
    <time_frame>within 2 min before putting the misoprostol into the vagina</time_frame>
    <description>at the moment of the introduction of misoprostol into the vagina</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Abortion Early</condition>
  <arm_group>
    <arm_group_label>Dry Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 µg of dry misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wet misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 µg of wet misoprostol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dry misoprostol</intervention_name>
    <description>400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation</description>
    <arm_group_label>Dry Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>wet misoprostol</intervention_name>
    <description>400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation</description>
    <arm_group_label>Wet misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with abortion (less than 12 weeks of pregnancy)

        Exclusion Criteria:

          -  congestive heart failure

          -  chronic pulmonary disease

          -  hypovolemic shock

          -  twins

          -  Marfan syndrome

          -  septic abortion (fever, pus , leukocytosis &gt;14,000)

          -  known allergies to misoprostol

          -  blood dyscrasia

          -  open cervical (≥ 1cm)

          -  use of intrauterine device
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo F Savaris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>WHO. The Prevention and management of unsafe abortion: report of a technical working group, Geneva, 12-15 April 1992. 1993</citation>
  </reference>
  <reference>
    <citation>Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000 Oct;14(5):839-54. Review.</citation>
    <PMID>11023804</PMID>
  </reference>
  <reference>
    <citation>Grimes DA, Benson J, Singh S, Romero M, Ganatra B, Okonofua FE, Shah IH. Unsafe abortion: the preventable pandemic. Lancet. 2006 Nov 25;368(9550):1908-19. Review.</citation>
    <PMID>17126724</PMID>
  </reference>
  <reference>
    <citation>Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1;367(9516):1066-74. Review.</citation>
    <PMID>16581405</PMID>
  </reference>
  <reference>
    <citation>Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007223. doi: 10.1002/14651858.CD007223.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jan 31;1:CD007223.</citation>
    <PMID>23543549</PMID>
  </reference>
  <reference>
    <citation>Fong YF, Singh K, Prasad RN. A comparative study using two dose regimens (200 microg or 400 microg) of vaginal misoprostol for pre-operative cervical dilatation in first trimester nulliparae. Br J Obstet Gynaecol. 1998 Apr;105(4):413-7.</citation>
    <PMID>9609268</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

